CRSP
Price
$46.85
Change
+$1.46 (+3.22%)
Updated
Oct 11 closing price
17 days until earnings call
GMAB
Price
$23.53
Change
-$0.18 (-0.76%)
Updated
Oct 11 closing price
24 days until earnings call
Ad is loading...

CRSP vs GMAB

Header iconCRSP vs GMAB Comparison
Open Charts CRSP vs GMABBanner chart's image
CRISPR Therapeutics AG
Price$46.85
Change+$1.46 (+3.22%)
Volume$1.11M
CapitalizationN/A
Genmab A/S ADS
Price$23.53
Change-$0.18 (-0.76%)
Volume$2.01M
CapitalizationN/A
View a ticker or compare two or three
CRSP vs GMAB Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GMAB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
CRSP vs. GMAB commentary
Oct 13, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and GMAB is a StrongBuy.

COMPARISON
Comparison
Oct 13, 2024
Stock price -- (CRSP: $46.85 vs. GMAB: $23.53)
Brand notoriety: CRSP and GMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 108% vs. GMAB: 342%
Market capitalization -- CRSP: $4B vs. GMAB: $15.44B
CRSP [@Biotechnology] is valued at $4B. GMAB’s [@Biotechnology] market capitalization is $15.44B. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileGMAB’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • GMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, CRSP is a better buy in the long-term than GMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 3 TA indicator(s) are bullish while GMAB’s TA Score has 5 bullish TA indicator(s).

  • CRSP’s TA Score: 3 bullish, 4 bearish.
  • GMAB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, GMAB is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а +3.26% price change this week, while GMAB (@Biotechnology) price change was +0.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.

Reported Earning Dates

CRSP is expected to report earnings on Feb 18, 2025.

GMAB is expected to report earnings on Feb 19, 2025.

Industries' Descriptions

@Biotechnology (+0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($15.4B) has a higher market cap than CRSP($4B). CRSP (-25.160) and GMAB (-26.099) have similar YTD gains . GMAB has higher annual earnings (EBITDA): 7.88B vs. CRSP (-335.17M). GMAB has more cash in the bank: 15.7B vs. CRSP (484M). CRSP has less debt than GMAB: CRSP (231M) vs GMAB (1.02B). GMAB has higher revenues than CRSP: GMAB (19B) vs CRSP (200M).
CRSPGMABCRSP / GMAB
Capitalization4B15.4B26%
EBITDA-335.17M7.88B-4%
Gain YTD-25.160-26.09996%
P/E RatioN/A19.28-
Revenue200M19B1%
Total Cash484M15.7B3%
Total Debt231M1.02B23%
FUNDAMENTALS RATINGS
CRSP vs GMAB: Fundamental Ratings
CRSP
GMAB
OUTLOOK RATING
1..100
1356
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
10083
SMR RATING
1..100
9351
PRICE GROWTH RATING
1..100
6282
P/E GROWTH RATING
1..100
8592
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (63) in the Biotechnology industry is in the same range as GMAB (68) in the null industry. This means that CRSP’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's Profit vs Risk Rating (83) in the null industry is in the same range as CRSP (100) in the Biotechnology industry. This means that GMAB’s stock grew similarly to CRSP’s over the last 12 months.

GMAB's SMR Rating (51) in the null industry is somewhat better than the same rating for CRSP (93) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than CRSP’s over the last 12 months.

CRSP's Price Growth Rating (62) in the Biotechnology industry is in the same range as GMAB (82) in the null industry. This means that CRSP’s stock grew similarly to GMAB’s over the last 12 months.

CRSP's P/E Growth Rating (85) in the Biotechnology industry is in the same range as GMAB (92) in the null industry. This means that CRSP’s stock grew similarly to GMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPGMAB
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
57%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 3 days ago
64%
Momentum
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
68%
MACD
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
55%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
66%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
67%
Advances
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 4 days ago
67%
Declines
ODDS (%)
Bearish Trend 13 days ago
85%
Bearish Trend 11 days ago
65%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
78%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
65%
View a ticker or compare two or three
Ad is loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GMAB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X63193.023000747.933600
+1.20%
Bitcoin cryptocurrency
SPY579.583.45
+0.60%
SPDR® S&P 500® ETF Trust
GME20.83-0.08
-0.38%
GameStop Corp
AAPL227.55-1.49
-0.65%
Apple
TSLA217.80-20.97
-8.78%
Tesla

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+3.22%
BEAM - CRSP
73%
Closely correlated
+7.34%
NTLA - CRSP
71%
Closely correlated
+4.44%
EDIT - CRSP
68%
Closely correlated
+7.77%
PRME - CRSP
57%
Loosely correlated
+1.68%
RXRX - CRSP
57%
Loosely correlated
+7.12%
More

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
-0.76%
GNMSF - GMAB
62%
Loosely correlated
+2.14%
AXON - GMAB
47%
Loosely correlated
+1.45%
VIR - GMAB
45%
Loosely correlated
+3.41%
CRSP - GMAB
36%
Loosely correlated
+3.22%
TECH - GMAB
36%
Loosely correlated
+0.52%
More